The story of Viagra, originally marketed by copyright, presents a fascinating case study for investors considering the pharmaceutical sector. Although its groundbreaking success and creation of countless in revenue , the intellectual property lapse has opened the floodgates for alternative medications, significantly diminishing income opportunities